公开(公告)号：US20180319819A1

公开(公告)日：2018-11-08

申请号：US15769201

申请日：2016-10-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takatoshi YOGO ,  Masato YOSHIKAWA ,  Morihisa SAITOH ,  Taisuke KATOH ,  Tomohiro SEKI ,  Yoshihisa NAKADA

IPC: C07D519/00 ,  A61P25/00

CPC classification number: C07D519/00 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P1/16 ,  A61P13/12 ,  A61P25/00 ,  A61P31/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like.The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20170096422A1

公开(公告)日：2017-04-06

申请号：US15127970

申请日：2015-03-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tetsuya TSUKAMOTO ,  Yoshihisa NAKADA ,  Michiyo MOCHIZUKI ,  Takafumi TAKAI ,  Tomoya YUKAWA ,  Zenyu SHIOKAWA ,  Taisuke KATOH ,  Masaki SETOH ,  Ayumu SATO ,  Takafumi YUKAWA

IPC: C07D471/04 ,  C07D487/04 ,  C07B59/00 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07B59/002 ,  C07B2200/05 ,  C07D487/04 ,  C07D519/00

Abstract: Provided is a compound having a superior PKC inhibitory action, and useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like, or a salt thereof. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a superior PKC inhibitory action, and is useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like.